Editorial

. 2018 Dec;1(6):459-460.

doi: 10.1016/j.euo.2018.10.004. Epub 2018 Nov 10.

Building an Understanding of the Value of Docetaxel Plus Hormone Therapy in Prostate Cancer: An Ever-growing Evidence Base

Richard De Abreu Lourenco¹, Scott G Williams²

Affiliations

¹ Centre for Health Economics Research and Evaluation, University of Technology, Sydney, Australia. Electronic address: richard.deabreulourenco@chere.uts.edu.au.
² Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia.

PMID: 31158088
DOI: 10.1016/j.euo.2018.10.004

Editorial

Building an Understanding of the Value of Docetaxel Plus Hormone Therapy in Prostate Cancer: An Ever-growing Evidence Base

Richard De Abreu Lourenco et al. Eur Urol Oncol. 2018 Dec.

. 2018 Dec;1(6):459-460.

doi: 10.1016/j.euo.2018.10.004. Epub 2018 Nov 10.

Authors

Richard De Abreu Lourenco¹, Scott G Williams²

Affiliations

¹ Centre for Health Economics Research and Evaluation, University of Technology, Sydney, Australia. Electronic address: richard.deabreulourenco@chere.uts.edu.au.
² Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia.

PMID: 31158088
DOI: 10.1016/j.euo.2018.10.004

No abstract available

PubMed Disclaimer

Comment on

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.
Woods BS, Sideris E, Sydes MR, Gannon MR, Parmar MKB, Alzouebi M, Attard G, Birtle AJ, Brock S, Cathomas R, Chakraborti PR, Cook A, Cross WR, Dearnaley DP, Gale J, Gibbs S, Graham JD, Hughes R, Jones RJ, Laing R, Mason MD, Matheson D, McLaren DB, Millman R, O'Sullivan JM, Parikh O, Parker CC, Peedell C, Protheroe A, Ritchie AWS, Robinson A, Russell JM, Simms MS, Srihari NN, Srinivasan R, Staffurth JN, Sundar S, Thalmann GN, Tolan S, Tran ATH, Tsang D, Wagstaff J, James ND, Sculpher MJ. Woods BS, et al. Eur Urol Oncol. 2018 Dec;1(6):449-458. doi: 10.1016/j.euo.2018.06.004. Epub 2018 Sep 14. Eur Urol Oncol. 2018. PMID: 31158087 Free PMC article. Clinical Trial.

Similar articles

Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective.
Zheng HR, Wen F, Wu YF, Wheeler JRC, Li Q. Zheng HR, et al. Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12505. Epub 2016 May 3. Eur J Cancer Care (Engl). 2017. PMID: 27145493
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S. Fizazi K, et al. Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X. Epub 2015 May 28. Lancet Oncol. 2015. PMID: 26028518 Clinical Trial.
Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients.
Carles J, Gallardo E, Doménech M, Font A, Bellmunt J, Figols M, Mellado B, Sáez MI, Suárez C, Méndez MJ, Maroto P, Luque R, de Portugal T, Aldabo R, Bonfill T, Morales-Barrera R, García J, Maciá S, Maldonado X, Foro P. Carles J, et al. Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):344-352. doi: 10.1016/j.ijrobp.2018.10.005. Epub 2018 Oct 12. Int J Radiat Oncol Biol Phys. 2019. PMID: 30321689 Clinical Trial.
The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
McNamara M, Sweeney C, Antonarakis ES, Armstrong AJ. McNamara M, et al. Prostate Cancer Prostatic Dis. 2018 Sep;21(3):306-318. doi: 10.1038/s41391-017-0014-9. Epub 2017 Dec 20. Prostate Cancer Prostatic Dis. 2018. PMID: 29263421 Review.
Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.
Xu L, Pachynski RK. Xu L, et al. Curr Urol Rep. 2018 Aug 13;19(10):79. doi: 10.1007/s11934-018-0835-7. Curr Urol Rep. 2018. PMID: 30105573 Review.

See all similar articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Building an Understanding of the Value of Docetaxel Plus Hormone Therapy in Prostate Cancer: An Ever-growing Evidence Base

Affiliations

Building an Understanding of the Value of Docetaxel Plus Hormone Therapy in Prostate Cancer: An Ever-growing Evidence Base

Authors

Affiliations

Comment on

Similar articles

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Comment on

Similar articles

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical